[go: up one dir, main page]

WO2007098091A3 - Traitement de maladies hyperprolifératives avec un n-oxyde d'alcaloïde de la pervenche et des analogues correspondants - Google Patents

Traitement de maladies hyperprolifératives avec un n-oxyde d'alcaloïde de la pervenche et des analogues correspondants Download PDF

Info

Publication number
WO2007098091A3
WO2007098091A3 PCT/US2007/004252 US2007004252W WO2007098091A3 WO 2007098091 A3 WO2007098091 A3 WO 2007098091A3 US 2007004252 W US2007004252 W US 2007004252W WO 2007098091 A3 WO2007098091 A3 WO 2007098091A3
Authority
WO
WIPO (PCT)
Prior art keywords
vinca alkaloid
analogs
oxide
treatment
hyperproliferative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/004252
Other languages
English (en)
Other versions
WO2007098091A2 (fr
Inventor
John G Curd
John F W Keana
Alshad S Lalani
Paul B Westberg
Bradford S Goodwin
William David Henner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novacea Inc
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Priority to JP2008555403A priority Critical patent/JP5596924B2/ja
Priority to CA2642717A priority patent/CA2642717C/fr
Priority to EP07751041.0A priority patent/EP1989212B1/fr
Priority to CN2007800136264A priority patent/CN101421282B/zh
Publication of WO2007098091A2 publication Critical patent/WO2007098091A2/fr
Priority to US12/111,672 priority patent/US8048872B2/en
Priority to IL193500A priority patent/IL193500A/en
Anticipated expiration legal-status Critical
Publication of WO2007098091A3 publication Critical patent/WO2007098091A3/fr
Priority to US13/280,974 priority patent/US8883775B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des N-oxydes d'alcaloïde de la pervenche et d'analogues possédant une activité destinée à traiter des troubles hyperprolifératifs. L'invention concerne également des compositions pharmaceutiques et des procédés utilisant ces N-oxydes d'alcaloïde de la pervenche et d'analogues, seul ou en combinaison avec un ou plusieurs autres agents ou traitements actifs, en vue de traiter des troubles hyperprolifératifs.
PCT/US2007/004252 2006-02-17 2007-02-20 Traitement de maladies hyperprolifératives avec un n-oxyde d'alcaloïde de la pervenche et des analogues correspondants Ceased WO2007098091A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2008555403A JP5596924B2 (ja) 2006-02-17 2007-02-20 ビンカアルカロイドｎ酸化物および類似体による過剰増殖疾患の処置
CA2642717A CA2642717C (fr) 2006-02-17 2007-02-20 Traitement de maladies hyperproliferatives avec un n-oxyde d'alcaloide de la pervenche et des analogues correspondants
EP07751041.0A EP1989212B1 (fr) 2006-02-17 2007-02-20 Traitement de maladies hyperprolifératives avec un n-oxyde de vinca-alcaloïde et des analogues correspondants
CN2007800136264A CN101421282B (zh) 2006-02-17 2007-02-20 用长春花生物碱n-氧化物和类似物治疗过度增殖性疾病
US12/111,672 US8048872B2 (en) 2006-02-17 2008-04-29 Treatment of hyperproliferative diseases with vinca alkaloid N-oxide and analogs
IL193500A IL193500A (en) 2006-02-17 2008-08-17 Pharmaceuticals including n-oxide of Winka alkaloid analogue for the treatment of hyper-proliferative diseases
US13/280,974 US8883775B2 (en) 2006-02-17 2011-10-25 Treatment of hyperproliferative diseases with vinca alkaloid N-oxide analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77420406P 2006-02-17 2006-02-17
US60/774,204 2006-02-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/111,672 Continuation-In-Part US8048872B2 (en) 2006-02-17 2008-04-29 Treatment of hyperproliferative diseases with vinca alkaloid N-oxide and analogs

Publications (2)

Publication Number Publication Date
WO2007098091A2 WO2007098091A2 (fr) 2007-08-30
WO2007098091A3 true WO2007098091A3 (fr) 2008-08-28

Family

ID=38437916

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004252 Ceased WO2007098091A2 (fr) 2006-02-17 2007-02-20 Traitement de maladies hyperprolifératives avec un n-oxyde d'alcaloïde de la pervenche et des analogues correspondants

Country Status (7)

Country Link
US (2) US8048872B2 (fr)
EP (1) EP1989212B1 (fr)
JP (1) JP5596924B2 (fr)
CN (1) CN101421282B (fr)
CA (1) CA2642717C (fr)
IL (1) IL193500A (fr)
WO (1) WO2007098091A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20192120T1 (hr) 2008-09-23 2020-02-21 Nektar Therapeutics Postupak metronomskog doziranja kamptotecinskih prolijekova (e.g.peg-irinotekan)
US8946275B2 (en) 2008-10-21 2015-02-03 Threshold Pharmaceuticals, Inc. Treatment of cancer using hypoxia activated prodrugs
EP2429584A4 (fr) * 2009-05-13 2013-02-20 Genzyme Corp Procédés et compositions de traitement
EP2533847B1 (fr) * 2010-02-12 2019-12-25 Varian Medical Systems, Inc. Applicateur pour curiethérapie
US20130196000A1 (en) * 2012-01-31 2013-08-01 Ziopharm Oncology, Inc. Combination therapy including isophosphoramide mustard, analogs, or salts thereof
WO2013170719A1 (fr) * 2012-05-16 2013-11-21 石家庄以岭药业股份有限公司 Dérivés de vinorelbine, composition pharmaceutique, procédé de préparation s'y rapportant et leur application
WO2014022524A1 (fr) * 2012-07-31 2014-02-06 Nimble Epitech, Llc Composition pharmaceutique contenant un agent d'hypométhylation et un inhibiteur d'histone désacétylase
AU2013356664B2 (en) * 2012-12-03 2018-01-18 The Scripps Research Institute C20'-urea derivatives of Vinca alkaloids
JP6250710B2 (ja) * 2013-04-19 2017-12-20 曁南大学 ビンブラスチン誘導体の調製方法
CN104740602B (zh) * 2013-12-30 2018-10-30 暨南大学 长春碱及其类似物的应用
HU230462B1 (hu) * 2013-05-30 2016-07-28 Richter Gedeon Nyrt. Új bisz-indol alkaloidok mint rákellenes gyógyszerek
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
CN104817575B (zh) * 2015-03-12 2017-02-01 天津中医药大学 化合物、其提取方法、包含其的药物组合物及其用途
US11103159B2 (en) * 2016-03-04 2021-08-31 United States Of America As Represented By The Secretary Of The Air Force Exhaled breath hypoxia biomarkers
WO2018085877A1 (fr) * 2016-11-10 2018-05-17 The University Of Melbourne Méthode de traitement
JP2024500975A (ja) * 2020-12-23 2024-01-10 カスケード プロドラッグ インコーポレイテッド ビンカアルカロイドｎ－オキシドと免疫チェックポイント阻害剤との併用療法
WO2022266251A1 (fr) * 2021-06-16 2022-12-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions pour le traitement du psoriasis
CN117599071B (zh) * 2024-01-19 2024-04-09 中国中医科学院中药研究所 土贝母苷甲在制备用于治疗银屑病的药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303584A (en) * 1980-04-02 1981-12-01 Eli Lilly And Company Method of preparing vincristine
US4347249A (en) * 1979-07-17 1982-08-31 Agence Nationale De Valorisation De La Recherche (Anvar) Class of seco bis-indolic compounds which can be used as drugs and a process for the preparation thereof
US6242457B1 (en) * 1999-03-09 2001-06-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
US20050222190A1 (en) * 2004-03-30 2005-10-06 Curd John G 1,4-bis-N-oxide azaanthracenediones and the use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2434172A1 (fr) * 1978-08-24 1980-03-21 Anvar Nouveaux composes intermediaires utiles dans la synthese de derives bis-indoliques et procede pour leur preparation
US4307100A (en) 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
US4305878A (en) * 1981-01-15 1981-12-15 Allied Corporation Purifying ethyl tetrahydrofurfuryl ether by aqueous salt extraction
US5047528A (en) 1987-01-22 1991-09-10 University Of Bristish Columbia Process of synthesis of vinblastine and vincristine
USRE37449E1 (en) 1987-02-06 2001-11-13 University Of British Columbia Process of synthesis of 3′,4′-anhydrovinblastine, vinblastine and vincristine
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
US5654279A (en) 1996-03-29 1997-08-05 The Regents Of The University Of California Tissue destruction in cryosurgery by use of thermal hysteresis
US6027499A (en) 1997-05-23 2000-02-22 Fiber-Tech Medical, Inc. (Assignee Of Jennifer B. Cartledge) Method and apparatus for cryogenic spray ablation of gastrointestinal mucosa
US5885276A (en) 1997-12-02 1999-03-23 Galil Medical Ltd. Method and device for transmyocardial cryo revascularization
FR2779146B1 (fr) * 1998-06-02 2002-01-18 Roowin Nouveaux derives de vinca-alcaloides et procedes de preparation
US6383180B1 (en) 1999-01-25 2002-05-07 Cryocath Technologies Inc. Closed loop catheter coolant system
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US7238704B2 (en) * 2003-12-04 2007-07-03 Amr Technology, Inc. Vinca derivatives
EP1694330A4 (fr) * 2003-12-04 2009-06-24 Amr Technology Inc Derives de la vinorelbine
BRPI0519466B8 (pt) * 2004-12-30 2021-05-25 Pf Medicament dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347249A (en) * 1979-07-17 1982-08-31 Agence Nationale De Valorisation De La Recherche (Anvar) Class of seco bis-indolic compounds which can be used as drugs and a process for the preparation thereof
US4303584A (en) * 1980-04-02 1981-12-01 Eli Lilly And Company Method of preparing vincristine
US6242457B1 (en) * 1999-03-09 2001-06-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
US20050222190A1 (en) * 2004-03-30 2005-10-06 Curd John G 1,4-bis-N-oxide azaanthracenediones and the use thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CIBOTTI ET AL.: "Monoclonal antibodies to bis-indole alkaloids of Catharanthus roseus and their use in enzyme-linked immunosorbent assays", PHYTOCHEMISTRY, vol. 29, no. 7, 1990, pages 2109 - 2114, XP026616213 *
EL-SAYED ET AL.: "Catharanthus alkaloids. XXVIII. Confirming structural evidence and antineoplastic activity of the bisindole alkaloids leurosine-N'b-oxide (pleurosine), roseadine and vindolicine from Catharanthus roseus", JOURNAL OF NATURAL PRODUCTS, vol. 46, no. 4, 1983, pages 517 - 527, XP008130333 *
HUSSEY ET AL.: "High-performance liquid chromatographic and TLC determinations of deacetylvinblastine amide vindesine) and its monosulfate salt", JOURNAL OF PARMACEUTICAL SCIENCES, vol. 67, no. 9, 1978, pages 1319 - 1320, XP008130336 *
MANGENEY ET AL.: "5'-Noranhydrovinblastine. Prototype of a new class of vinblastine derivatives", TETRAHEDRON, vol. 35, 1979, pages 2175 - 2179, XP008130332 *
MUKHOPADHYAY ET AL.: "Catharanthus alkaloids. XXXV. Isolation of leurosidine N'b-oxide from Catharanthus roseus", JOURNAL OF NATURAL PRODUCTS, vol. 44, no. 5, 1981, pages 611 - 613, XP008130334 *
SPEARMAN ET AL.: "Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS14-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys", DRUG METABOLISM AND DISPOSITION, vol. 15, no. 5, 1987, pages 640 - 647, XP008130362 *
THIMMAIAH ET AL.: "Structural investigations of the products of vincristine sulfate formed after in vitro incubation of the alkaloid in bile of dogs", MICROCHEMICAL JOURNAL, vol. 41, no. 3, 1990, pages 320 - 326, XP008130174 *

Also Published As

Publication number Publication date
US8883775B2 (en) 2014-11-11
CA2642717C (fr) 2015-08-18
WO2007098091A2 (fr) 2007-08-30
CN101421282A (zh) 2009-04-29
JP2009527480A (ja) 2009-07-30
US20080305075A1 (en) 2008-12-11
US8048872B2 (en) 2011-11-01
US20120107230A1 (en) 2012-05-03
IL193500A (en) 2015-10-29
EP1989212B1 (fr) 2013-06-19
IL193500A0 (en) 2009-08-03
EP1989212A4 (fr) 2010-05-12
EP1989212A2 (fr) 2008-11-12
CN101421282B (zh) 2013-08-14
JP5596924B2 (ja) 2014-09-24
CA2642717A1 (fr) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2007098091A3 (fr) Traitement de maladies hyperprolifératives avec un n-oxyde d'alcaloïde de la pervenche et des analogues correspondants
WO2007098089A3 (fr) Traitment de maladies hyperprolifératives avec du n-oxide de méthotrexate et des analogues correspondants
WO2007095389A3 (fr) traitement de maladies hyperprolifEratives avec la camptothecine n-oxyde et des analogues de celle-ci
WO2007117381A3 (fr) Activateurs de glucokinase
WO2008021196A3 (fr) Procédés et compositions de traitement de troubles médicaux
TW200740804A (en) Glucokinase activators
WO2008011174A3 (fr) Inhibiteurs de la jak pour le traitement des syndromes myéloprolifératifs
WO2009126931A3 (fr) Thérapie combinatoire pour trouble bipolaire
WO2008033440A3 (fr) Traitement de maladies hyperprolifératives à l'aide d'anthraquinones
EP2514423A3 (fr) Procédé de traitement de la dégénérescence maculaire liée à l'âge (DMLA)
TWI372061B (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
MY157944A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associat ed with angiogenesis
WO2007100675A3 (fr) Procédé de traitement de la cellulite
WO2010006219A3 (fr) Utilisation d'un support comportant de la fibrine pour distribution de cellules souches
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2009045464A8 (fr) Méthodes de traitement de troubles neurologiques auto-immuns utilisant le cyclophosphamide
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
WO2008029169A3 (fr) Procédé de traitement de troubles respiratoires
WO2007058990A3 (fr) Therapie a base d’inhibiteurs de cytokine
WO2004110380A3 (fr) Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques
WO2006098603A3 (fr) Composition renfermant de l'isoorientine pour suppression d'histamine
WO2006074265A3 (fr) Therapie combinee et compositions pharmaceutiques utilisees dans le traitement des troubles inflammatoires
WO2008157747A8 (fr) Utilisation d'inhibition d'exonucléase i dans des procédés de thérapie et de diagnostic de maladies neurodégénératives, de maladies oculaires et de troubles mitochondriaux
WO2007100430A3 (fr) Analogues de cystisine et d'acétylcholine et procédés de traitement des troubles de l'humeur
WO2006086693A3 (fr) Dispositifs medicaux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 193500

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008555403

Country of ref document: JP

Ref document number: 2642717

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007751041

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200780013626.4

Country of ref document: CN